PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
70.90
-0.15 (-0.21%)
At close: Jan 20, 2026
Market Cap27.73B
Revenue (ttm)n/a
Net Income (ttm)-242.62M
Shares Out391.09M
EPS (ttm)-0.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume226,800
Average Volume246,736
Open71.50
Previous Close71.05
Day's Range69.80 - 71.50
52-Week Range8.68 - 77.00
Betan/a
RSI58.13
Earnings DateMay 17, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-... [Read more]

Sector Materials
Founded 2008
Employees 53
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.